Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Inclusion Criteria:

- Healthy participants as determined by no clinically significant deviation from normal
in medical history, physical examination, electrocardiograms, and clinical laboratory
determinations

- All participants must have hemoglobin, hematocrit, and platelets within normal limits
at screening

- All participants must have activated partial thromboplastin time, prothrombin time,
and international normalized ratio within normal limits at screening

Exclusion Criteria:

- Any current or past history or risk for tuberculosis:

- Active tuberculosis requiring treatment within the previous 3 years. All participants
will be required to have a QuantiFERON tuberculosis Gold or T-SPOT tuberculosis test
performed at screening. Also excluded are participants with evidence of a past
tuberculosis infection without documented adequate therapy. Participants with a
positive QuantiFERON tuberculosis Gold or T-SPOT tuberculosis test at screening will
not be eligible for the study. A QuantiFERON tuberculosis Gold or T-SPOT tuberculosis
test performed within 4 weeks of dosing on Day 1 is acceptable as long as there is
documentation of a negative result.

- Current clinical, radiographic, or laboratory evidence of active tuberculosis

- A history of herpes zoster